TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3316311

Group type: EXPERIMENTAL
Intervention: Ticarcillin disodium plus moxalactam (T+M)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Piperacillin plus moxalactam (P+M)
Number of subjects: 53
Study: 31597485

Group type: EXPERIMENTAL
Intervention: Pump bottle dispensing device
Number of subjects: 94

Group type: COMPARATOR
Intervention: Squeeze bottle dispensing device
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Label treatments (two levels)
Number of subjects: 94
Study: 30379244

Group type: EXPERIMENTAL
Intervention: Preheating with a forced air system for 20 minutes (38°C)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual care (heating with a cotton sheet and blanket)
Number of subjects: 86
Study: 27878767

Group type: EXPERIMENTAL
Intervention: Intravenous phenobarbital
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intravenous valproate
Number of subjects: 73
Study: 25652672

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 38
Study: 24124503

Group type: EXPERIMENTAL
Intervention: Cogmed's RoboMemo program
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 21072756

Group type: EXPERIMENTAL
Intervention: Phosphorylcholine-coated tympanostomy tube
Number of subjects: 240

Group type: COMPARATOR
Intervention: Uncoated tympanostomy tube
Number of subjects: 240
Study: 19166423

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (lansoprazole 30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, twice a day for 7 days)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Proton pump inhibitor (lansoprazole 30 mg, twice a day for 7 days)
Number of subjects: 47
Study: 17054858

Group type: EXPERIMENTAL
Intervention: Autologous cytokine-induced killer cell (CIK) fusion (1.1 - 1.5 x 10^10) via peripheral vein or hepatic artery, administered once every 3 - 4 weeks for 4 times, then once every 4 weeks for 4 times
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no CIK fusion)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Autologous CIK fusion
Number of subjects: 64
Study: 14642552

Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling (TTC)
Number of subjects: 12905

Group type: COMPARATOR
Intervention: Mailed reminders
Number of subjects: 12905
Study: 10801994

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8839716

Group type: EXPERIMENTAL
Intervention: Slow Rotation (SR) chemotherapy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Rapid Rotation (RR) chemotherapy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Overall group (SR + RR)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Failure to achieve remission at day 28
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Children aged < 1 year
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Children aged 1-10 years
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Children with WBC >= 100/nl in RR group
Number of subjects: 201
Study: 1311152

Group type: EXPERIMENTAL
Intervention: Self-help dietary intervention introduced by a nurse
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Self-help dietary intervention for individuals responsible for meal preparation
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Self-help dietary intervention
Number of subjects: 242
Study: 6324832

Group type: EXPERIMENTAL
Intervention: Magnesium trisilicate mixture B.P.C.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sodium citrate 0.3 mol litre‐1 mixture
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 78
Study: 30076171

Group type: EXPERIMENTAL
Intervention: ozanimod (treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo (control)
Number of subjects: 0
Study: 29394942

Group type: EXPERIMENTAL
Intervention: Self-reported mental illness
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Being unemployed
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Overall EQ-5D scores
Number of subjects: 437
Study: 27427325

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen during exercise training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Compressed medical air during exercise training (control)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Strength training with supplemental oxygen
Number of subjects: 29
Study: 25209738

Group type: EXPERIMENTAL
Intervention: Continuous drisapersen 6 mg/kg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Intermittent drisapersen 6 mg/kg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 22732469

Group type: EXPERIMENTAL
Intervention: Cobicistat (COBI) 150 mg QD for 7 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ritonavir (RTV) 100 mg QD for 7 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 54
Study: 19906767

Group type: COMPARATOR
Intervention: Cane use
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: TheraTogs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hip abductor taping
Number of subjects: 13

Group type: COMPARATOR
Intervention: Baseline (without aids)
Number of subjects: 13
Study: 17898345

Group type: EXPERIMENTAL
Intervention: Earlier ages at onset of major depressive disorder
Number of subjects: 4041

Group type: EXPERIMENTAL
Intervention: Age at onset
Number of subjects: 4041
Study: 15173480

Group type: EXPERIMENTAL
Intervention: Comprehensive home safety education and free safety devices
Number of subjects: 96

Group type: COMPARATOR
Intervention: Focused, injury-specific ED discharge instructions
Number of subjects: 96
Study: 11534317

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Dalteparin) at a dose of 200 I.E./kg body weight/d
Number of subjects: 138

Group type: COMPARATOR
Intervention: Unfragmented heparin
Number of subjects: 138
Study: 9508182

Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg subcutaneously every 4 weeks; n = 69)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Surgical ovariectomy (n = 67)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 138
Study: 7999651

Group type: EXPERIMENTAL
Intervention: Needle set A (16-gauge Tuohy needle and a 26-gauge spinal needle that extends 13 mm beyond the tip of the Tuohy needle)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Needle set B (16-gauge Tuohy needle with an aperture in its curve for the insertion of a 26-gauge spinal needle that protrudes 10 mm beyond the tip of the epidural needle)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Infusion of bupivacaine (0.1%) with fentanyl (2 micrograms/mL)
Number of subjects: 40
Study: 2667633

Group type: EXPERIMENTAL
Intervention: Oxybutinin hydrochloride
Number of subjects: 23

Group type: COMPARATOR
Intervention: Propanthiline bromide
Number of subjects: 23
Study: 4207904

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation followed by surgery
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation followed by surgery
Number of subjects: 3

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 3
Study: 31214836

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 65
Study: 27546817

Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg with perindopril 2-4 mg (active treatment)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 25639993

Group type: EXPERIMENTAL
Intervention: Housing First
Number of subjects: 950

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 950
Study: 22717145

Group type: EXPERIMENTAL
Intervention: Therapist behaviours in internet-delivered cognitive behaviour therapy (iCBT)
Number of subjects: 44
Study: 21641117

Group type: EXPERIMENTAL
Intervention: Prenatal cognitive behavioral stress management (CBSM) intervention
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Low risk comparison (LRC) group
Number of subjects: 86
Study: 19892237

Group type: EXPERIMENTAL
Intervention: Mechanical valve (MP)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Bioprosthetic valve (BP)
Number of subjects: 310
Study: 16328904

Group type: EXPERIMENTAL
Intervention: Patient Generated Index (PGI) at 6 and 24 weeks post-stroke
Number of subjects: 92
Study: 12221157

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (60 micro g)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study: 9865236

Group type: EXPERIMENTAL
Intervention: 2,3-dimercaptosuccinic acid 1400 mg/d (1000 mg/m2) in the first week and 1050 mg/d (750 mg/m2) during the next 2 weeks with a repeat course 3 weeks later
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo capsules for the same schedule
Number of subjects: 21
Study: 7890238

Group type: EXPERIMENTAL
Intervention: Oligopeptide diet
Number of subjects: 44

Group type: COMPARATOR
Intervention: Amino acid diet
Number of subjects: 44
Study: 2090833

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study: 377130

Group type: EXPERIMENTAL
Intervention: ionic contrast media
Number of subjects: 0

Group type: COMPARATOR
Intervention: non-ionic contrast media (implied control)
Number of subjects: 0
Study: 31947784

Group type: EXPERIMENTAL
Intervention: Interdisciplinary program (healthy eating, exercise, cognitive behavioral therapy)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Interdisciplinary program
Number of subjects: 74
Study: 30289426

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (BWL) treatment
Number of subjects: 110

Group type: COMPARATOR
Intervention: Migraine education (ME)
Number of subjects: 110
Study: 24899570

Group type: EXPERIMENTAL
Intervention: Oral preparation containing hyaluronic acid (Oralvisc®)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 22903518

Group type: EXPERIMENTAL
Intervention: EEG-biofeedback
Number of subjects: 38

Group type: COMPARATOR
Intervention: SC-biofeedback
Number of subjects: 38

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 38
Study: 21934454

Group type: EXPERIMENTAL
Intervention: Contraceptive curriculum (hormonal contraceptives provided onsite at no cost)
Number of subjects: 889
Study: 19164788

Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg bolus followed by continuous infusion for 48 hours)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo (bolus and infusion)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Lidocaine (total dose mg/kg)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Lidocaine (lower doses)
Number of subjects: 277
Study: 18033941

Group type: EXPERIMENTAL
Intervention: Web-based instruction for anatomical interpretation in maxillofacial cone beam CT (CBCT)
Number of subjects: 3
Study: 15306109

Group type: EXPERIMENTAL
Intervention: Cialis 20 mg taken on demand
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 11884002

Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy (PEG)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Nasogastric Tube (NGT)
Number of subjects: 122
Study: 9498886

Group type: EXPERIMENTAL
Intervention: Propofol 1.0 mg/kgxh
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kgxh
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kgxh
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol 0.1 mg/kg bolus followed by 1.0 mg/kgxh
Number of subjects: 24
Study: 8192438

Group type: EXPERIMENTAL
Intervention: 4 g of oral acyclovir daily
Number of subjects: 139

Group type: COMPARATOR
Intervention: 1 g of oral acyclovir daily
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both doses of acyclovir
Number of subjects: 139
Study: 3359913

Group type: EXPERIMENTAL
Intervention: Vigilance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rest
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: After a meal
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stationary spiking activity during Vigilance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stationary spiking activity during Rest
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stationary spiking activity during Stress
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stationary spiking activity after a meal
Number of subjects: 40
Study: 29235894

Group type: EXPERIMENTAL
Intervention: Pacritinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ruxolitinib
Number of subjects: 0
Study: 26823552

Group type: EXPERIMENTAL
Intervention: Ketoanalogue‐supplemented vegetarian very low‐protein diet (KD) (0.3 g/kg vegetable proteins and 1 cps/5 kg ketoanalogues per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional low‐protein diet (LPD) (0.6 g/kg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoanalogue‐supplemented vegetarian very low‐protein diet (KD)
Number of subjects: 0
Study: 23621351

Group type: EXPERIMENTAL
Intervention: Calvarial bone blocks (group 1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Iliac crest bone grafts (group 2)
Number of subjects: 9
Study: 24401580

Group type: EXPERIMENTAL
Intervention: P(cv‐a) CO2 guided fluid therapy (group P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ScvO2 guided fluid therapy (group S)
Number of subjects: 40
Study: 20150206

Group type: EXPERIMENTAL
Intervention: Diet based on increased consumption of fresh fruit and vegetables (intervention group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Free diet (control group)
Number of subjects: 120
Study: 18006187

Group type: EXPERIMENTAL
Intervention: Suppression of thoughts of eating chocolate
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Expression of thoughts of eating chocolate
Number of subjects: 134

Group type: COMPARATOR
Intervention: Verbalise only control group
Number of subjects: 134
Study: 16206364

Group type: EXPERIMENTAL
Intervention: Patient self-report checklist for adverse events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigator-reported adverse event instruments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rheumatology Common Toxicity Criteria
Number of subjects: 0
Study: 11823658

Group type: EXPERIMENTAL
Intervention: Intravenous tPA
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 10051051

Group type: EXPERIMENTAL
Intervention: Neoral (CsA‐ME)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sandimmune (CsA‐SIM)
Number of subjects: 0
Study: 7486086

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% (A 125)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% (A 25)
Number of subjects: 30

Group type: COMPARATOR
Intervention: saline 0.9% (A 0)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% (B 25)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo (B 0)
Number of subjects: 30
Study: 1979376

Group type: EXPERIMENTAL
Intervention: Immediate splinting
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sonographic surveillance for 2 weeks
Number of subjects: 79
Study: 7006615

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 31557344

Group type: EXPERIMENTAL
Intervention: Partner-reported alcohol consumption
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Partner-reported AUDIT score
Number of subjects: 247

Group type: COMPARATOR
Intervention: Self-reported AUDIT score
Number of subjects: 247
Study: 24535044

Group type: EXPERIMENTAL
Intervention: Group-1 (uncertain, with intercessory prayer)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group-2 (uncertain, no intercessory prayer)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (informed, no intervention)
Number of subjects: 45
Study: 26130344

Group type: EXPERIMENTAL
Intervention: TXA group (2 intravenous injections of 1 g TXA pre- and post-operatively)
Number of subjects: 60
Study: 22576416

Group type: EXPERIMENTAL
Intervention: Electro‐myostimulation (EMS)
Number of subjects: 20
Study: 22269195

Group type: EXPERIMENTAL
Intervention: Mouth rinse containing Ocimum gratissimum (Og)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mouth rinse containing chlorhexidine digluconate (CLX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (mouth rinse with no antiseptic agents)
Number of subjects: 30
Study: 19250558

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (indapamide SR 1.5 mg +/‐ perindopril 2‐4 mg)
Number of subjects: 3763

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 3763
Study: 17697550

Group type: EXPERIMENTAL
Intervention: Homemade tropisetron hydrochloride
Number of subjects: 118

Group type: COMPARATOR
Intervention: Navoban (positive control agent)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Adverse events occurrence rate
Number of subjects: 118
Study: 15662146

Group type: EXPERIMENTAL
Intervention: d-methylphenidate hydrochloride (d-MPH) 10 mg twice-a-day
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: d-methylphenidate hydrochloride (d-MPH)
Number of subjects: 89
Study: 11696143

Group type: EXPERIMENTAL
Intervention: 2 mg x kg(‐1) 0.2% ropivacaine + S‐ketamine 0.5 mg x kg(‐1)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 2 mg x kg(‐1) 0.2% ropivacaine + clonidine 2 microg x kg(‐1)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 2 mg x kg(‐1) 0.2% ropivacaine
Number of subjects: 63
Study: 11074735

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (conjugated equine estrogens alone or in combination with progestins)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study: 8923552

Group type: EXPERIMENTAL
Intervention: One-line or two-line pitched-from-vertical stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oblique one-line or two-line stimulus from an erect plane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitched-from-vertical lines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus sequencing or subject naivety
Number of subjects: 0
Study: 1315445

Group type: EXPERIMENTAL
Intervention: + oxaprotiline
Number of subjects: 10

Group type: COMPARATOR
Intervention: - oxaprotiline
Number of subjects: 10
Study: 3932228

Group type: EXPERIMENTAL
Intervention: HB 420 (1.75 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: HB 419 (2.5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: HB 420 and Semi‐Euglucon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 10
Study: 30218695

Group type: EXPERIMENTAL
Intervention: GFF MDI (28.8 μg/10 μg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GFF MDI (14.4 μg/10 μg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GP MDI (28.8 μg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GP MDI (14.4 μg)
Number of subjects: 100
Study: 26412294

Group type: EXPERIMENTAL
Intervention: Continuum intervention
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: Biogenetic intervention
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 1189
Study: 24662344

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 8 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 28 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (healthy people), N=31
Number of subjects: 59
Study: 22168465

Group type: EXPERIMENTAL
Intervention: Boiled egg food challenge
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Raw egg food challenge
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Gal d 1 positivity
Number of subjects: 68

Group type: COMPARATOR
Intervention: Skin tests and other IgE tests
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Multiple specific IgE detection by ISAC
Number of subjects: 68
Study: 20100958

Group type: EXPERIMENTAL
Intervention: Cetuximab with taxane/carboplatin (T/C)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Taxane/carboplatin (T/C) without cetuximab
Number of subjects: 676
Study: 17594216

Group type: EXPERIMENTAL
Intervention: PBLI-DMEDS module
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 0
Study: 16151816

Group type: EXPERIMENTAL
Intervention: Oxybutynin-TDS
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study: 12241543

Group type: EXPERIMENTAL
Intervention: Aldosterone (12 pmol.min(‐1).kg(‐1) for 4 h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prednisolone (single 50 mg dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10095333

Group type: EXPERIMENTAL
Intervention: Antipronation taping technique
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Temporary felt orthosis
Number of subjects: 14

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 14
Study: 7587422

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol, 50 micrograms twice a day for seven doses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms) after salmeterol period
Number of subjects: 10
Study: 2262371

Group type: EXPERIMENTAL
Intervention: Two hyperthermia treatments
Number of subjects: 70

Group type: COMPARATOR
Intervention: Six hyperthermia treatments
Number of subjects: 70
Study: 31128522

Group type: EXPERIMENTAL
Intervention: Baduanjin
Number of subjects: 69

Group type: COMPARATOR
Intervention: Brisk walking
Number of subjects: 69

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 69
Study: 30391912

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) administration (1 µg/kg loading dose before anaesthesia induction and 0.5 µg/kg/h infusion during surgery)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Saline control (CON group)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) administration
Number of subjects: 190